de Franchis, R. et al. Baveno VII – renewing consensus in portal hypertension. J. Hepatol. 76, 959–974 (2022).

Article  PubMed  Google Scholar 

Kaplan, D. E. et al. AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 79, 1180–1211 (2024).

Article  PubMed  Google Scholar 

Ripoll, C. et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133, 481–488 (2007).

Article  CAS  PubMed  Google Scholar 

Paternostro, R. et al. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD. J. Hepatol. 81, 827–836 (2024).

Article  PubMed  Google Scholar 

Wadhawan, M., Dubey, S., Sharma, B. C. & Sarin, S. K. Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and Child’s status. Dig. Dis. Sci. 51, 2264–2269 (2006).

Article  CAS  PubMed  Google Scholar 

Villanueva, C. et al. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. J. Hepatol. 77, 1014–1025 (2022).

Article  CAS  PubMed  Google Scholar 

Villanueva, C. et al. β-Blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 393, 1597–1608 (2019).

Article  CAS  PubMed  Google Scholar 

Sangro, B. et al. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J. Hepatol. 82, 315–374 (2025).

Article  Google Scholar 

Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update. J. Hepatol. 84, 631–654 (2026).

Article  PubMed  Google Scholar 

Wolf, E., Rich, N. E., Marrero, J. A., Parikh, N. D. & Singal, A. G. Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis. Hepatology 73, 713–725 (2021).

Article  PubMed  Google Scholar 

Singal, A. G. et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology https://doi.org/10.1097/HEP.0000000000000466 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Faitot, F. et al. Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation. Hepatology 62, 179–187 (2015).

Article  PubMed  Google Scholar 

Allaire, M. et al. Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosis. Dig. Liver Dis. 51, 86–94 (2019).

Article  PubMed  Google Scholar 

Choi, J. W. et al. Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma. Eur. Radiol. 28, 2184–2193 (2018).

Article  PubMed  Google Scholar 

Müller, L. et al. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. United Eur. Gastroenterol. J. 10, 41–53 (2022).

Google Scholar 

Allaire, M. et al. Real-world outcomes of atezolizumab–bevacizumab in hepatocellular carcinoma: the prospective French CHIEF cohort. Liver Int. 45, e70337 (2025).

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Alessio, A. et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child–Pugh A and B cirrhosis: a real-world study. Hepatology 76, 1000–1012 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Ripoll, C. et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J. Hepatol. 50, 923–928 (2009).

Article  PubMed  PubMed Central  Google Scholar 

Liao, X. et al. The β-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor κB signaling. Oncol. Rep. 24, 1669–1676 (2010).

CAS  PubMed  Google Scholar 

Al-Wadei, H. A., Al-Wadei, M. H. & Schuller, H. M. Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer. Drugs 20, 477–482 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pérez-Páramo, M. et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 31, 43–48 (2000).

Article  PubMed  Google Scholar 

Thiele, M. et al. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. Liver Int. 35, 2009–2016 (2015).

Article  CAS  PubMed  Google Scholar 

Abraldes, J. G. et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136, 1651–1658 (2009).

Article  CAS  PubMed  Google Scholar 

Pollo-Flores, P. et al. Three months of simvastatin therapy vs placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig. Liver Dis. 47, 957–963 (2015).

Article  CAS  PubMed  Google Scholar 

Tarar, Z. I. et al. Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. World J. Exp. Med. 14, 98543 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Wang, Y. et al. A meta-analysis of statin use and risk of hepatocellular carcinoma. Can. J. Gastroenterol. Hepatol. 2022, 5389044 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Memel, Z. N. et al. Aspirin use is associated with a reduced incidence of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol. Commun. 5, 133–143 (2021).

Article  CAS  PubMed  Google Scholar 

Allaire, M., Rudler, M. & Thabut, D. Portal hypertension and hepatocellular carcinoma: des liaisons dangereuses…. Liver Int. 41, 1734–1743 (2021).

Article  PubMed  Google Scholar 

Aliseda, D. et al. The impact of portal hypertension assessment method on the outcomes of hepatocellular carcinoma resection: a meta-analysis of matched cohort and prospective studies. Ann. Surg. 280, 46–55 (2024).

Article  PubMed  Google Scholar 

Huang, Z. et al. Prognostic value of liver stiffness measurement for the liver-related surgical outcomes of patients under hepatic resection: a meta-analysis. PLoS ONE 13, e0190512 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Pavlovic, N., Rani, B., Gerwins, P. & Heindryckx, F. Platelets as key factors in hepatocellular carcinoma. Cancers 11, 1022 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lai, Q. et al. Platelets and hepatocellular cancer: bridging the bench to the clinics. Cancers 11, 1568 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Llop, E. et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J. Hepatol. 56, 103–108 (2012).

Article  PubMed  Google Scholar 

Omata, M. et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol. Int. 11, 317–370 (2017).